相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer.
V. Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 x FEC versus 3 x FEC/3 x Docetaxel
Eva J. Kantelhardt et al.
BMC CANCER (2011)
The plasmin-antiplasmin system: structural and functional aspects
Johann Schaller et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea
Jerzy Jankun et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2011)
Inhibition of Urokinase Activity Reduces Primary Tumor Growth and Metastasis Formation in a Murine Lung Carcinoma Model
Ingrid Henneke et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
RNA Aptamers as Conformational Probes and Regulatory Agents for Plasminogen Activator Inhibitor-1
Jeppe B. Madsen et al.
BIOCHEMISTRY (2010)
Risk Group Selection in Primary Breast Cancer According to ASCO Recommended Biomarkers Onkotype DX and uPA/PAI-1: First Experience from Prospective Multicenter WSG Plan B Trial
T. Degenhardt et al.
CANCER RESEARCH (2010)
Personalized treatment of early-stage breast cancer: Present concepts and future directions
Nadia Harbeck et al.
CANCER TREATMENT REVIEWS (2010)
Optimizing Chemotherapy Regimens for Patients With Early-Stage Breast Cancer
Efrat Dotan et al.
CLINICAL BREAST CANCER (2010)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers
Catharine M. Sturgeon et al.
CLINICAL CHEMISTRY (2010)
UPA and PAI-1 Analysis from Fixed Tissues - New Perspectives for a Known Set of Predictive Markers
K. Malinowsky et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
Manfred Schmitt et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2010)
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
Karin Mengele et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2010)
Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib
D. Goldstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The molecular pathology of cancer
Timothy J. R. Harris et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.
Miguel Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
ASCO Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors
Timothy D. Gilligan et al.
JOURNAL OF ONCOLOGY PRACTICE (2010)
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays
Kathy S. Albain et al.
BREAST (2009)
The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Salvatore Ulisse et al.
CURRENT CANCER DRUG TARGETS (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Feasibility of Measuring the Prognostic Factors uPA and PAI-1 in Core Needle Biopsy Breast Cancer Specimens
Christoph Thomssen et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
New insights into the molecular mechanisms of the fibrinolytic system
D. C. Rijken et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
MOLECULAR ORIGINS OF CANCER Gene-Expression Signatures in Breast Cancer
Christos Sotiriou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects
Manfred Schmitt et al.
BREAST CARE (2008)
Regional breast center at the university cancer center Dresden
Wolfgang Distler et al.
BREAST CARE (2008)
Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer
Lori J. Goldstein
BREAST CARE (2008)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Catharine M. Sturgeon et al.
CLINICAL CHEMISTRY (2008)
A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes
Deepti Navaratna et al.
FASEB JOURNAL (2008)
Trial Assessing Individualized Options for Treatment for breast cancer: the TAILORx trial
Jo Anne Zujewski et al.
FUTURE ONCOLOGY (2008)
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer
Sharad A. Ghamande et al.
GYNECOLOGIC ONCOLOGY (2008)
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Miguel Martin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Anti-cancer therapies targeting the tumor stroma
Valeska Hofmeister et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties
Jurgen Joossens et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
PAI-1 - A potential therapeutic target in cancer
Peter A. Andreasen
CURRENT DRUG TARGETS (2007)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and αvβ5 integrin
Paola Franco et al.
JOURNAL OF CELL SCIENCE (2006)
Effect of a novel octapeptide urokinase fragment, A°6, on experimental choroidal neovascularization in the monkey
Hyoung J. Koh et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer:: A phase I trial
A Berkenblit et al.
GYNECOLOGIC ONCOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE UROLOGY (2005)
Gene expression profiling of breast cancer: A new tumor marker
LJ van't Veer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties
M Bruncko et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6
HJ Koh et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Facts and controversies in systemic treatment of metastatic breast cancer
C Bernard-Marty et al.
ONCOLOGIST (2004)
A urokinase-derived peptide (Å6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis
DD Boyd et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Protease degradomics:: A new challenge for proteomics
C López-Otin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 8377 breast cancer patients
MP Look et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
F Jänicke et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Neoadjuvant therapy in breast cancer: Can we define its role?
MS Aapro
ONCOLOGIST (2001)
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin
K Mishima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo
YJ Guo et al.
FASEB JOURNAL (2000)
Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite
V Nienaber et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
